Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 36.2% in October

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 95,100 shares, an increase of 36.2% from the October 15th total of 69,800 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is presently 0.1 days.

Vivos Therapeutics Price Performance

Shares of VVOS stock remained flat at $3.12 during trading hours on Thursday. The company’s stock had a trading volume of 212,297 shares, compared to its average volume of 485,799. The company’s fifty day moving average is $2.78 and its 200 day moving average is $2.51. The firm has a market capitalization of $14.88 million, a P/E ratio of -0.44 and a beta of 7.71. Vivos Therapeutics has a 52-week low of $1.91 and a 52-week high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.60) earnings per share for the quarter. Vivos Therapeutics had a negative net margin of 85.90% and a negative return on equity of 652.32%. The firm had revenue of $4.05 million for the quarter. On average, research analysts expect that Vivos Therapeutics will post -3.13 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets raised their price objective on Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research note on Tuesday, August 20th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.